Alain Saraux1, Jacques Benichou2, Loic Guillevin3, Latifa Idbrik4, Chantal Job-Deslandre5, Jean Sibilia6, Marc Soudant7, Daniel Wendling8, Francis Guillemin7. 1. Rheumatology Department, Cavale Blanche University Hospital, and Université Bretagne Occidentale, Brest, France. 2. Department of Biostatistics, Rouen University Hospital and INSERM U657, Institute for Biomedical Research, University of Rouen, Rouen, France. 3. Department of Internal Medicine, Hôpital Cochin-Paris Univ 2, Paris, France. 4. Inserm, CIC-EC CIE6, CHU de Brabois, Vandoeuvre-lès-Nancy; and Inserm-Transfert, Paris, France. 5. Service de Rhumatologie A, Hôpital Cochin, AP-HP, Université Paris-Descartes, Paris, France. 6. Service de Rhumatologie, CHU Hautepierre, Service de Rhumatologie, Strasbourg, France. 7. Inserm, CIC-EC 1433, CHU Nancy, Epidémiologie et Evaluation Cliniques, Nancy, France. 8. Service de Rhumatologie, CHU de Besançon, Besançon; and EA 4266, Université de Franche-Comté, Besançon, France.
Abstract
OBJECTIVES: Limited information is available about the characteristics of patients with active inflammatory rheumatic diseases who start TNF-α antagonist therapy. Our objective was to assess TNF-α antagonist prescription patterns in this context in France. METHODS: Between 2007 and 2009, 102 rheumatologists, internists, and pediatricians in French university hospitals and private practice prospectively recruited biologics-naïve patients with active rheumatoid arthritis (RA) (DAS28>3.2 despite methotrexate therapy), spondyloarthritis (SA) (BASDAI≥4 despite non-steroidal anti-inflammatory drug [NSAID] use), and juvenile idiopathic arthritis (JIA) (unresponsive to methotrexate). Patients were monitored prospectively for 1 year. RESULTS: Of the 543 RA, 287 SA, and 53 JIA patients included in the study, 382 RA, 171 SA, and 28 JIA patients had complete follow-up data available after 1 year. Among these patients, 110/382 (28.8%) with RA, 81/171 (47.4%) with SA, and 26/28 (92.9%) with JIA received at least one TNF-α antagonist dose during the 1-year follow-up. The main physician-reported reason for not starting TNF-α antagonists in patients with RA or SA was low disease activity (72% for RA and 67% for SA); absence of TNF-α antagonist therapy was due to patient refusal in only 10% and to contraindications in 6% to 7% of cases. CONCLUSIONS: In France, TNF-α antagonists, which are fully reimbursed by the national health insurance system, were used almost routinely in JIA patients unresponsive to methotrexate and were given to about half the SA patients with BASDAI≥4 despite NSAID use and a third of RA patients with DAS28>3.2 despite methotrexate therapy.
OBJECTIVES: Limited information is available about the characteristics of patients with active inflammatory rheumatic diseases who start TNF-α antagonist therapy. Our objective was to assess TNF-α antagonist prescription patterns in this context in France. METHODS: Between 2007 and 2009, 102 rheumatologists, internists, and pediatricians in French university hospitals and private practice prospectively recruited biologics-naïve patients with active rheumatoid arthritis (RA) (DAS28>3.2 despite methotrexate therapy), spondyloarthritis (SA) (BASDAI≥4 despite non-steroidal anti-inflammatory drug [NSAID] use), and juvenile idiopathic arthritis (JIA) (unresponsive to methotrexate). Patients were monitored prospectively for 1 year. RESULTS: Of the 543 RA, 287 SA, and 53 JIA patients included in the study, 382 RA, 171 SA, and 28 JIA patients had complete follow-up data available after 1 year. Among these patients, 110/382 (28.8%) with RA, 81/171 (47.4%) with SA, and 26/28 (92.9%) with JIA received at least one TNF-α antagonist dose during the 1-year follow-up. The main physician-reported reason for not starting TNF-α antagonists in patients with RA or SA was low disease activity (72% for RA and 67% for SA); absence of TNF-α antagonist therapy was due to patient refusal in only 10% and to contraindications in 6% to 7% of cases. CONCLUSIONS: In France, TNF-α antagonists, which are fully reimbursed by the national health insurance system, were used almost routinely in JIA patients unresponsive to methotrexate and were given to about half the SA patients with BASDAI≥4 despite NSAID use and a third of RApatients with DAS28>3.2 despite methotrexate therapy.